Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BVS NASDAQ:LMAT NASDAQ:TMDX NYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$8.11+2.3%$9.65$5.81▼$11.25$662.43M0.67633,870 shs1.13 million shsLMATLeMaitre Vascular$91.62+0.2%$106.84$79.00▼$118.01$2.09B0.54305,638 shs273,343 shsTMDXTransMedics Group$68.45+1.4%$92.00$60.10▼$156.00$2.33B1.911.95 million shs1.38 million shsWRBYWarby Parker$25.09+2.9%$23.84$14.96▼$31.00$2.61B1.963.52 million shs2.44 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus+2.27%-10.09%-19.78%-4.25%+810,999,900.00%LMATLeMaitre Vascular+0.22%-7.18%-18.23%-13.90%+13.96%TMDXTransMedics Group+1.36%-2.85%-31.56%-53.64%-44.77%WRBYWarby Parker+2.68%-1.86%+8.44%-8.21%+16.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$8.11+2.3%$9.65$5.81▼$11.25$662.43M0.67633,870 shs1.13 million shsLMATLeMaitre Vascular$91.62+0.2%$106.84$79.00▼$118.01$2.09B0.54305,638 shs273,343 shsTMDXTransMedics Group$68.45+1.4%$92.00$60.10▼$156.00$2.33B1.911.95 million shs1.38 million shsWRBYWarby Parker$25.09+2.9%$23.84$14.96▼$31.00$2.61B1.963.52 million shs2.44 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus+2.27%-10.09%-19.78%-4.25%+810,999,900.00%LMATLeMaitre Vascular+0.22%-7.18%-18.23%-13.90%+13.96%TMDXTransMedics Group+1.36%-2.85%-31.56%-53.64%-44.77%WRBYWarby Parker+2.68%-1.86%+8.44%-8.21%+16.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 3.00Buy$14.0072.63% UpsideLMATLeMaitre Vascular 2.75Moderate Buy$112.6022.90% UpsideTMDXTransMedics Group 2.46Hold$134.0095.76% UpsideWRBYWarby Parker 2.64Moderate Buy$29.5017.60% UpsideCurrent Analyst Ratings BreakdownLatest BVS, WRBY, TMDX, and LMAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026TMDXTransMedics Group UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/26/2026TMDXTransMedics Group Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$85.00 ➝ $75.005/22/2026WRBYWarby Parker CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/22/2026BVSBioventus Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$14.005/20/2026LMATLeMaitre Vascular Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/19/2026WRBYWarby Parker Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/11/2026WRBYWarby Parker Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Hold (C-)5/8/2026WRBYWarby Parker UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$25.00 ➝ $27.005/8/2026WRBYWarby Parker Telsey Advisory GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$32.00 ➝ $33.005/7/2026WRBYWarby Parker BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $34.005/6/2026LMATLeMaitre Vascular Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$568.09M1.19$1.30 per share6.22$2.76 per share2.94LMATLeMaitre Vascular$249.60M8.39$2.91 per share31.50$17.35 per share5.28TMDXTransMedics Group$605.49M3.91$3.98 per share17.20$13.79 per share4.96WRBYWarby Parker$871.91M3.08$0.65 per share38.75$3.48 per share7.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus$22.73M$0.4119.789.221.024.94%29.97%9.52%N/ALMATLeMaitre Vascular$57.73M$2.7133.8128.022.5424.35%15.36%9.78%8/4/2026 (Estimated)TMDXTransMedics Group$190.29M$4.4015.5618.91N/A27.04%22.38%8.46%7/30/2026 (Estimated)WRBYWarby Parker$1.64M$0.021,254.8862.71N/A0.15%2.30%1.18%8/6/2026 (Estimated)Latest BVS, WRBY, TMDX, and LMAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026WRBYWarby Parker$0.11$0.03-$0.08$0.03$239.44 million$242.45 million5/6/2026Q1 2026BVSBioventus$0.09$0.15+$0.06$0.04N/A$132.09 million5/5/2026Q1 2026LMATLeMaitre Vascular$0.66$0.68+$0.02$0.68$66.67 million$66.55 million5/5/2026Q1 2026TMDXTransMedics Group$0.62$0.30-$0.32$0.20$174.44 million$173.93 million3/5/2026Q4 2025BVSBioventus$0.22$0.24+$0.02$0.21N/A$157.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/ALMATLeMaitre Vascular$1.001.09%+16.05%36.90%14 YearsTMDXTransMedics GroupN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ALatest BVS, WRBY, TMDX, and LMAT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2026LMATLeMaitre Vascularquarterly$0.251%5/21/20265/21/20266/4/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.081.691.13LMATLeMaitre Vascular0.4214.3212.20TMDXTransMedics Group1.706.746.19WRBYWarby ParkerN/A2.332.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%LMATLeMaitre Vascular84.64%TMDXTransMedics Group99.67%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%LMATLeMaitre Vascular7.40%TMDXTransMedics Group6.90%WRBYWarby Parker16.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20083.54 million55.97 millionN/ALMATLeMaitre Vascular49022.85 million21.16 millionOptionableTMDXTransMedics Group21034.56 million32.18 millionOptionableWRBYWarby Parker4,036107.09 million89.10 millionOptionableBVS, WRBY, TMDX, and LMAT HeadlinesRecent News About These CompaniesRational Advisors Inc. Purchases New Position in Warby Parker Inc. $WRBY1 hour ago | marketbeat.comWarby Parker Announces Participation in Upcoming 2026 Baird Global Consumer, Technology & Services ConferenceMay 28, 2026 | businesswire.comKing Luther Capital Management Corp Has $9.22 Million Position in Warby Parker Inc. $WRBYMay 28, 2026 | marketbeat.comWarby Parker Inc. (NYSE:WRBY) Given Average Rating of "Moderate Buy" by BrokeragesMay 27, 2026 | americanbankingnews.comWarby Parker Inc. (NYSE:WRBY) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 27, 2026 | marketbeat.comFuture of 'A-Eye': Warby Parker co-CEOs on the company's new AI glassesMay 26, 2026 | youtube.comYWellington Shields Capital Management LLC Buys New Shares in Warby Parker Inc. $WRBYMay 26, 2026 | marketbeat.comSimplify Asset Management Inc. Buys New Position in Warby Parker Inc. $WRBYMay 25, 2026 | marketbeat.comThe Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind...May 24, 2026 | marketbeat.comNeil Harris Blumenthal Sells 63,040 Shares of Warby Parker (NYSE:WRBY) StockMay 22, 2026 | insidertrades.com47,191 Shares in Warby Parker Inc. $WRBY Purchased by Fortis Group Advisors LLCMay 22, 2026 | marketbeat.comWarby Parker (NYSE:WRBY) CEO Sells $1,893,091.20 in StockMay 21, 2026 | marketbeat.comWarby Parker Offers Glimpse of Google-Powered Smart GlassesMay 20, 2026 | pymnts.comWarby Parker slides as investors compare its smart glasses to the Meta Ray-Ban lineMay 20, 2026 | msn.comWarby Parker Stock Slumps 11% as Questions Cloud Its Google Gemini AI Eyewear RevealMay 19, 2026 | barrons.comWarby Parker (NYSE:WRBY) Trading Down 6.6% - Here's WhyMay 19, 2026 | marketbeat.comGoogle and Samsung's Warby Parker and Gentle Monster Glasses Are Coming This FallMay 19, 2026 | cnet.comWarby Parker Unveils First Intelligent Eyewear DesignMay 19, 2026 | businesswire.comTimesSquare Capital Management LLC Boosts Stock Holdings in Warby Parker Inc. $WRBYMay 19, 2026 | marketbeat.comUBS Remains a Hold on Warby Parker (WRBY)May 17, 2026 | theglobeandmail.comWarby Parker (NYSE:WRBY) Director Sells $140,205.33 in StockMay 16, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026BVS, WRBY, TMDX, and LMAT Company DescriptionsBioventus NASDAQ:BVS$8.11 +0.18 (+2.27%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$8.11 +0.00 (+0.01%) As of 05:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.LeMaitre Vascular NASDAQ:LMAT$91.62 +0.20 (+0.22%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$91.58 -0.04 (-0.04%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.TransMedics Group NASDAQ:TMDX$68.45 +0.92 (+1.36%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$68.25 -0.20 (-0.29%) As of 07:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Warby Parker NYSE:WRBY$25.08 +0.71 (+2.89%) Closing price 06/2/2026 03:59 PM EasternExtended Trading$25.04 -0.05 (-0.18%) As of 07:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? FirstCash Turns Pawn Into a Growth Machine HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
